EP1003516A4 - Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen - Google Patents

Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen

Info

Publication number
EP1003516A4
EP1003516A4 EP99935334A EP99935334A EP1003516A4 EP 1003516 A4 EP1003516 A4 EP 1003516A4 EP 99935334 A EP99935334 A EP 99935334A EP 99935334 A EP99935334 A EP 99935334A EP 1003516 A4 EP1003516 A4 EP 1003516A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
methods
side effects
reduced side
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99935334A
Other languages
English (en)
French (fr)
Other versions
EP1003516A1 (de
Inventor
Bernard Bouscarel
Kunihiko Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
George Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Washington University filed Critical George Washington University
Publication of EP1003516A1 publication Critical patent/EP1003516A1/de
Publication of EP1003516A4 publication Critical patent/EP1003516A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP99935334A 1998-06-18 1999-06-18 Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen Withdrawn EP1003516A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8978198P 1998-06-18 1998-06-18
US89781P 1998-06-18
PCT/US1999/013906 WO1999065493A1 (en) 1998-06-18 1999-06-18 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Publications (2)

Publication Number Publication Date
EP1003516A1 EP1003516A1 (de) 2000-05-31
EP1003516A4 true EP1003516A4 (de) 2006-07-12

Family

ID=22219554

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99935334A Withdrawn EP1003516A4 (de) 1998-06-18 1999-06-18 Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen

Country Status (7)

Country Link
EP (1) EP1003516A4 (de)
JP (1) JP2002518332A (de)
CN (1) CN1325305A (de)
AU (1) AU764370B2 (de)
CA (1) CA2300892A1 (de)
IL (1) IL134592A0 (de)
WO (1) WO1999065493A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
WO2000069390A2 (en) 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
EP1372571A4 (de) * 2001-03-20 2006-06-07 New Century Pharmaceuticals Methode und zubereitungen zur optimierung von blut- und gewebe-stabilität von camptothecin und anderen albumin-bindenden wirkstoffen
WO2007113687A2 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
US20170246190A1 (en) * 2014-10-21 2017-08-31 Johnpro Biotech Inc. Methods and formulation for improving oral availability of cpt-11 while reducing cpt-11 induced gastrointestinal toxicity in cancer therapy
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH02270822A (ja) * 1989-02-07 1990-11-05 Duphar Internatl Res Bv 経口再水和溶液調製用の発泡製品
EP0524579A1 (de) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Verbesserte und dosierte orale Formulierungen von Dideoxypurinenukleosiden
WO1994028911A1 (en) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS FOR USE IN THE REGULATION OF SUBNORMAL pH VALUES IN THE INTESTINAL TRACT AND FOR TREATMENT OF BOWEL DISEASES
WO1996006635A1 (en) * 1994-08-31 1996-03-07 Cortecs Limited Pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH02270822A (ja) * 1989-02-07 1990-11-05 Duphar Internatl Res Bv 経口再水和溶液調製用の発泡製品
EP0524579A1 (de) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Verbesserte und dosierte orale Formulierungen von Dideoxypurinenukleosiden
WO1994028911A1 (en) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS FOR USE IN THE REGULATION OF SUBNORMAL pH VALUES IN THE INTESTINAL TRACT AND FOR TREATMENT OF BOWEL DISEASES
WO1996006635A1 (en) * 1994-08-31 1996-03-07 Cortecs Limited Pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ARAKI E ET AL: "RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 84, no. 6, June 1993 (1993-06-01), pages 697 - 702, XP008059720, ISSN: 0910-5050 *
ATSUMI R ET AL: "METABOLISM OF IRINOTECAN TO SN-38 IN A TISSUE-ISOLATED TUMOR MODEL", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 18, no. 7, July 1995 (1995-07-01), pages 1024 - 1026, XP008059867, ISSN: 0918-6158 *
HERBEN V M M ET AL: "CLINICAL PHARMACOKINETICS OF TOPOTECAN", CLINICAL PHARMACOKINETICS, LEA & FEBIGER, PHILADELPHIA, PA, US, vol. 31, no. 2, 1996, pages 85 - 102, XP000874360 *
KOBAYASGI K. ET AL.: "Reduced Irinotecan-induced side-effects by the oral Alkalinization", PROC. AM. SOC. CLIN. ONCOL., vol. 18, no. 35, 15 May 1999 (1999-05-15), 35th annual meeting of ASCO, pages 492A, XP002370825 *
KOBAYASHI K ET AL: "UPTAKE MECHANISM OF IRINOTECAN (CPT-11) AND ITS METABOLITE (SN-38) BY HAMSTER INTESTINAL CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 114, no. 4, 15 April 1998 (1998-04-15), pages A626 - A627, XP008059718, ISSN: 0016-5085 *
MATSUZAKI Y ET AL: "CELLULAR UPTAKE AND TOXICITY OF IRINOTECAN AND ITS ACTIVE METABOLITE, SN-38 IN HAMSTER INTESTINE AND HUMAN COLON CANCER CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 116, no. 4, PART 2, April 1999 (1999-04-01), pages A906,ABSTRNOG3940, XP008059942, ISSN: 0016-5085 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 13 30 November 1998 (1998-11-30) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) *
SCHELLENS J H M ET AL: "PHARMACOKINETICS (PK), CLINICAL PHARMACODYNAMICS (PD), AND SAFETY OF CHRONIC ORAL TOPOTECAN (T), IN A PHASE STUDY", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 31, no. 6, 1 November 1995 (1995-11-01), pages S192,ABSTRNO926, XP008059770, ISSN: 0959-8049 *
SCOTT D O ET AL: "URINARY AND BILIARY DISPOSITION OF THE LACTONE AND CARBOXYLATE FORMS OF 20(S)-CAMPTOTHECIN IN RATS", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 22, no. 3, May 1994 (1994-05-01), pages 438 - 442, XP008059680, ISSN: 0090-9556 *
See also references of WO9965493A1 *

Also Published As

Publication number Publication date
WO1999065493A1 (en) 1999-12-23
AU764370B2 (en) 2003-08-14
IL134592A0 (en) 2001-04-30
CA2300892A1 (en) 1999-12-23
JP2002518332A (ja) 2002-06-25
WO1999065493A9 (en) 2000-03-23
AU5083399A (en) 2000-01-05
CN1325305A (zh) 2001-12-05
EP1003516A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
AP9700939A0 (en) Compounds and methods for the treatment of cancer
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
HK1116339A1 (en) Methods of administering epothilone analogs for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
IL142588A0 (en) Therapy for improving cognition
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
AU2508597A (en) Drug for the treatment of tumours
AU7377200A (en) Combination therapy including camptothecin
NZ512210A (en) Camptothecin analogs useful for treating cancer and leukemia
EP1003516A4 (de) Verfahren zur verabreichung von camptothecin verbindungen zur krebsbehandlung mit verringerten nebenwirkungen
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP0200805A3 (en) Improved cancer treatment with temozolomide
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
AU1940800A (en) Combination therapy for the treatment of sepsis
IL148815A0 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
HK1046019A1 (zh) 診斷和治療肺癌的組合物和方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB NL

17P Request for examination filed

Effective date: 20000320

A4 Supplementary search report drawn up and despatched

Effective date: 20060612

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060912